Progressive Familial Intrahepatic Cholestasis (PFIC) Type 3 in Two Sicilian Siblings of Nonconsanguineous Parents

Isodiana Crupi
Pediatrician, San Piero Patti, Messina, Italy

E-mail: crupi.isodi@libero.it

Received January 24, 2010; Revised April 19, 2010; Accepted May 11, 2010; Published June 14, 2010

KEYWORDS: cholestasis, biliary cirrhosis, autosomal-recessive disorders

Progressive familial intrahepatic cholestasis (PFIC) is a group of three types of autosomal-recessive disorders, characterized by cholestasis and biliary cirrhosis due to defects in specific transport proteins involved in bile formation[1,2,3]. Clinical presentation usually occurs first in childhood, with progressive cholestasis that leads to failure to thrive, hepatic failure, and liver transplantation. PFIC type 3 is caused by a variety of mutations in ABCB4 (ATP-binding cassette, subfamily B, member 4), the gene encoding multidrug resistance protein 3 (MDR3), which codes for flippase, an enzyme responsible for the transport of phospholipid molecules between cell membranes. Initial treatment with ursodeoxycholic acid, cholestyramine, rifampin, and fat-soluble vitamins is supportive, while patients must have a liver transplant when liver dysfunction is significant[4,5].

Two brothers, affected by PFIC type 3, were referred to the pediatrician. The first was diagnosed at the age of 4 years. He presented no signs or symptoms until, at the age of 1 year, due to a swollen abdomen and failure to thrive, he was prescribed laboratory tests (antigliadin antibodies, antieンドomysial antibodies) and a sweat test that all gave normal results. Later, possibly due to an allergic reaction with urticaria, he was given antihistaminic therapy, with no relief. This led to referral to an allergologist, who prescribed a series of blood exams that showed AST 165 UI/l (normal range: 15–55), ALT 180 UI/l (5–45), and γ-GT 80 UI/l (5–32). The child was then admitted to a pediatric gastroenterology center for further examination. After a series of exams to exclude other causes of liver disease, the child was referred to a pediatric hepatology center for a liver biopsy that resulted in a diagnosis of PFIC type 3. Genomic DNA analysis showed homozygosity for mutations in the human MDR3 gene with heterozygosity of the nonconsanguineous parents.

In the second brother, the disorder was diagnosed at birth, the only sign being a prolonged jaundice. Blood exams showed elevated serum liver enzymes and increased γ-GT activity (three times the normal values). Genomic DNA analysis showed homozygosity for the same mutations of the sibling in the human MDR3 gene. Both brothers, with nonconsanguineous parents, are in good clinical condition at 11 years and 1 year of age, respectively. They are under medical treatment with cholestyramine ursodeoxycholic acid, and fat-soluble vitamins.

De Vree et al.[3] reported two cases of PFIC type 3: the first was a Turkish boy of healthy consanguineous parents; the second, a North African boy of first-cousin parents. To our knowledge, the
presence of mutations in the human MDR3 gene has been described so far only in siblings of consanguineous parents.

ACKNOWLEDGMENTS

The author wishes to thank Dr. Lorenzo Curtò for his contribution to the management of the paper.

REFERENCES


This article should be cited as follows:
